Relapsed/Refractory Tumors research hub

Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)

This study is looking into a new treatment for children and young adults with certain types of cancer that haven't responded to other treatments. It will check how safe the new treatment is and if it helps shrink the tumours.